Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC

Video

James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).

James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non—small cell lung cancer (NSCLC).

Radiation has tremendous potential in stimulating the immune system, explains Larner. Radiation increases antigen presentation and dendritic cell activity through the damage associated molecular pattern with the release of ATP, calreticulin, high mobility group proteins, and so forth. This results in the so called abscopal effect, says Larner.

However, there is a lot that is unknown about how to integrate radiation with immune checkpoint blockade, such as which comes first and the optimal therapeutic dose. Recently, several molecular pathways have been identified, including the cGAS-STING pathway, where damaged DNA goes into the cytosol and turns on an interferon response that leads to dendritic cell stimulation. Determining the optimal dose is important, explains Larner, because if too high or too low of a dose is given, there may not be a response.

The real future lies in understanding the potential permutations and pathways that are involved in potentiating the immune response and whether radiation can aid in enabling a systemic effect, states Larner.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.